|1.||Alam, Raffique: 1 article (03/2011)|
|2.||Khan, Moosa: 1 article (03/2011)|
|3.||Gul, Ali: 1 article (03/2011)|
|4.||Das, Dial: 1 article (03/2011)|
|5.||Akova, Yonca A: 1 article (09/2006)|
|6.||Gedik, Sansal: 1 article (09/2006)|
|7.||Gür, Sirel: 1 article (09/2006)|
|8.||Onakoya, A O: 1 article (03/2006)|
|9.||Olasimbo, O O: 1 article (03/2006)|
|10.||Adefule, A K: 1 article (03/2006)|
|1.||Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
03/01/2006 - "Lodoxamide 0.1 ophthalmic solution is highly effective in alleviating the clinical signs and symptoms of Vernal Keratoconjunctivitis and its antiallergic activity is exerted by inhibiting migration of inflammatory cells mainly eosinophlis."
04/15/1994 - "Lodoxamide 0.1% ophthalmic solution was significantly (P < .05) more effective than placebo in lowering severity scores for epithelial disease and corneal staining, evidence of the superior efficacy of lodoxamide 0.1% ophthalmic solution in reversing the corneal complications commonly associated with moderate to severe vernal keratoconjunctivitis. "
12/01/1996 - "Lodoxamide is an antiallergic drug acting as a mast-cell stabilizer, which is effective in the treatment of allergic conjunctivitis. "
03/01/2011 - "Safety and efficacy of lodoxamide in vernal keratoconjunctivitis."
03/01/2006 - "To ascertain the efficacy of Lodoxamide 0.1 in the reduction of Clinicopathological signs of the conjunctiva in Vernal Keratoconjunctivitis. "
01/01/2002 - "Lodoxamide was effective in reduction of symptoms and clinical signs of the ocular allergies. "
01/01/2001 - "The purpose of this work is to assess the efficacy of lodoxamide, a new antiallergic medication for topical use, whose advantage is low or absent risk of adverse side effects, in alleviating local allergic reactions of the eye in patients with dry eye. "
01/01/2002 - "To evaluate the effectiveness of lodoxamide in the therapy and prophylaxis of the ocular allergies. "
01/01/2001 - "[Evaluation of efficacy and safety of sterile solution of lodoxamide in patients with ocular allergy]."
04/01/1996 - "Lodoxamide was shown to ideally inhibit various aspects of the allergic reaction: clinical signs and symptoms in both the early and late phases, the primarily EPR-related peak of histamine release, and the primarily LPR-related changes in tear cytology."
|3.||Eye Diseases (Eye Disease)
01/01/2002 - "[Evaluation of the efficacy and safety of lodoxamide in patients with allergic eye diseases]."
07/01/1992 - "Patients given lodoxamide 0.1% showed a significantly more rapid and greater improvement in their signs and symptoms of allergic eye disease than patients given sodium cromoglycate 2%. "
07/01/1992 - "Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. "
07/01/1992 - "135 patients were entered into a 28-day randomized double-masked multicentre study comparing the efficacy and short-term safety of lodoxamide 0.1% ophthalmic solution (Alomide--Alcon Laboratories), a mast cell stabilizer, with sodium cromoglycate 2% ophthalmic solution (Opticrom--Fisons Pharmaceuticals) in the treatment of allergic eye disease. "
02/05/1982 - "The protective effect of lodoxamide on antigen-induced bronchospasm. "
12/01/1981 - "Further studies are warranted to compare the effectiveness of lodoxamide with that of cromolyn sodium in protection against antigen-induced bronchospasm and to evaluate the relative efficacy and safety of lodoxamide in long-term clinical trials."
09/01/1997 - "The results, obtained by evaluating the main clinical signs and symptoms (itching, lacrimation, hyperaemia, palpebral oedema and chemosis), demonstrate with statistically significant differences that lodoxamide inhibits the conjunctival response to exposure to the allergen with greater efficacy than spaglumic acid, and for a longer duration. "
01/01/1996 - "Statistically significant trends toward improvement were noted in the lodoxamide group in resolving papillae on day 30, decreasing corneal staining on days 30 and 60, relieving photophobia on day 60, tearing on days 7, 30 and 60 and itching on days 30 and 60. "
05/01/1997 - "Lodoxamide significantly reduced tryptase levels (P < 0.01), neutrophils (P < 0.04), and eosinophils (P < 0.01) in the tear fluid and significantly inhibited ocular itching (P < 0.02) when compared with that of placebo. "
04/01/2001 - "However, relative to levocabastine, conjunctival discharge, photophobia and lacrimation were significantly reduced by lodoxamide at months 1, 2 and 3, itching at months 2 and 3, and bulbar conjunctiva at month 3. The temporal improvement of superior tarsal papillae did not differ significantly between treatments. "
06/15/1992 - "On various follow-up visits, the clinical efficacy of lodoxamide 0.1% was statistically superior to cromolyn sodium 4% in alleviating four of the primary symptoms (itching, tearing, foreign-body sensation, and discomfort) and five of the primary signs (Trantas' dots, palpebral conjunctival changes, bulbar conjunctival hyperemia, erythema/swelling of the eyelids and periorbital tissues, and epithelial disease). "
|1.||Cromolyn Sodium (Cromoglicic Acid)
|2.||Ophthalmic Solutions (Eye Drops)
|5.||N-acetyl-1-aspartylglutamic acid (NAAGA)
|7.||Eosinophil Cationic Protein
|8.||Histamine (Histamine Dihydrochloride)
|1.||Artificial Eye (Artificial Eyes)